EA012724B1 - Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2 (pge2) - Google Patents
Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2 (pge2) Download PDFInfo
- Publication number
- EA012724B1 EA012724B1 EA200702534A EA200702534A EA012724B1 EA 012724 B1 EA012724 B1 EA 012724B1 EA 200702534 A EA200702534 A EA 200702534A EA 200702534 A EA200702534 A EA 200702534A EA 012724 B1 EA012724 B1 EA 012724B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inflammatory
- aminocarbazole
- group
- pce
- production
- Prior art date
Links
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title description 12
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title description 3
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 12
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 9
- 208000035475 disorder Diseases 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 36
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 206010015150 Erythema Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 231100000321 erythema Toxicity 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000009956 adenocarcinoma Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 8
- 230000003449 preventive effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 229940127293 prostanoid Drugs 0.000 description 13
- 150000003814 prostanoids Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 150000001716 carbazoles Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 150000002066 eicosanoids Chemical class 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001272 neurogenic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000003331 prothrombotic effect Effects 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 230000002666 vasoprotective effect Effects 0.000 description 2
- PBUBQPXTELKFNB-UHFFFAOYSA-N (3-amino-9H-carbazol-1-yl)-phenylmethanone Chemical class C(C1=CC=CC=C1)(=O)C1=CC(=CC=2C3=CC=CC=C3NC1=2)N PBUBQPXTELKFNB-UHFFFAOYSA-N 0.000 description 1
- LRSYZHFYNDZXMU-UHFFFAOYSA-N 9h-carbazol-3-amine Chemical compound C1=CC=C2C3=CC(N)=CC=C3NC2=C1 LRSYZHFYNDZXMU-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000633401 Homo sapiens Neuropeptide Y receptor type 5 Proteins 0.000 description 1
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000008013 morphine dependence Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000020964 regulation of blood coagulation Effects 0.000 description 1
- 230000010451 regulation of platelet aggregation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 231100000513 vascular toxicity Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000909A ITMI20050909A1 (it) | 2005-05-19 | 2005-05-19 | Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2- |
| PCT/EP2006/004348 WO2006122680A1 (en) | 2005-05-19 | 2006-05-03 | Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200702534A1 EA200702534A1 (ru) | 2008-04-28 |
| EA012724B1 true EA012724B1 (ru) | 2009-12-30 |
Family
ID=35219704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200702534A EA012724B1 (ru) | 2005-05-19 | 2006-05-03 | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2 (pge2) |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8686021B2 (enExample) |
| EP (1) | EP1881826B1 (enExample) |
| JP (1) | JP5086991B2 (enExample) |
| KR (1) | KR101312579B1 (enExample) |
| CN (1) | CN101166528B (enExample) |
| AR (1) | AR054126A1 (enExample) |
| AT (1) | ATE473739T1 (enExample) |
| AU (1) | AU2006246688B2 (enExample) |
| BR (1) | BRPI0609718A2 (enExample) |
| CA (1) | CA2604562C (enExample) |
| DE (1) | DE602006015457D1 (enExample) |
| DK (1) | DK1881826T3 (enExample) |
| EA (1) | EA012724B1 (enExample) |
| ES (1) | ES2347174T3 (enExample) |
| GE (1) | GEP20094738B (enExample) |
| IL (1) | IL186072A (enExample) |
| IT (1) | ITMI20050909A1 (enExample) |
| MX (1) | MX2007013491A (enExample) |
| PL (1) | PL1881826T3 (enExample) |
| PT (1) | PT1881826E (enExample) |
| SI (1) | SI1881826T1 (enExample) |
| UA (1) | UA94044C2 (enExample) |
| WO (1) | WO2006122680A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| EP2119705A1 (en) | 2008-05-14 | 2009-11-18 | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. | 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor |
| US8880004B2 (en) | 2009-05-14 | 2014-11-04 | Qualcomm Incorporated | System and method for resolving conflicts between air interfaces in a wireless communication system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399631B1 (en) * | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| WO2002096902A1 (en) * | 2001-05-29 | 2002-12-05 | Boehringer Ingelheim International Gmbh | Carbazole derivatives and their use for the preparation of pharmaceutical compositions for the treatment of npy related diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241368A (ja) * | 1997-02-18 | 2002-08-28 | Shionogi & Co Ltd | 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物 |
| AU6000900A (en) | 1999-07-23 | 2001-02-13 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| JP2003507424A (ja) * | 1999-08-26 | 2003-02-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体 |
| CA2403307A1 (en) * | 2001-10-23 | 2003-04-23 | Neurogen Corporation | Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives |
| KR20030042344A (ko) * | 2001-11-22 | 2003-05-28 | 한국생명공학연구원 | 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제 |
| ES2193875B2 (es) * | 2002-04-09 | 2005-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos. |
| KR100402714B1 (ko) * | 2002-12-23 | 2003-11-13 | 한국생명공학연구원 | 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도 |
-
2005
- 2005-05-19 IT IT000909A patent/ITMI20050909A1/it unknown
-
2006
- 2006-05-03 CN CN2006800144162A patent/CN101166528B/zh not_active Expired - Fee Related
- 2006-05-03 PL PL06753538T patent/PL1881826T3/pl unknown
- 2006-05-03 EP EP06753538A patent/EP1881826B1/en not_active Not-in-force
- 2006-05-03 PT PT06753538T patent/PT1881826E/pt unknown
- 2006-05-03 MX MX2007013491A patent/MX2007013491A/es active IP Right Grant
- 2006-05-03 DK DK06753538.5T patent/DK1881826T3/da active
- 2006-05-03 KR KR1020077029661A patent/KR101312579B1/ko not_active Expired - Fee Related
- 2006-05-03 WO PCT/EP2006/004348 patent/WO2006122680A1/en not_active Ceased
- 2006-05-03 JP JP2008511591A patent/JP5086991B2/ja not_active Expired - Fee Related
- 2006-05-03 GE GEAP200610441A patent/GEP20094738B/en unknown
- 2006-05-03 DE DE602006015457T patent/DE602006015457D1/de active Active
- 2006-05-03 BR BRPI0609718-9A patent/BRPI0609718A2/pt not_active IP Right Cessation
- 2006-05-03 AT AT06753538T patent/ATE473739T1/de active
- 2006-05-03 SI SI200630781T patent/SI1881826T1/sl unknown
- 2006-05-03 UA UAA200713598A patent/UA94044C2/ru unknown
- 2006-05-03 AU AU2006246688A patent/AU2006246688B2/en not_active Ceased
- 2006-05-03 EA EA200702534A patent/EA012724B1/ru not_active IP Right Cessation
- 2006-05-03 CA CA2604562A patent/CA2604562C/en not_active Expired - Fee Related
- 2006-05-03 US US11/909,393 patent/US8686021B2/en not_active Expired - Fee Related
- 2006-05-03 ES ES06753538T patent/ES2347174T3/es active Active
- 2006-05-17 AR ARP060101981A patent/AR054126A1/es not_active Application Discontinuation
-
2007
- 2007-09-19 IL IL186072A patent/IL186072A/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399631B1 (en) * | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| WO2002096902A1 (en) * | 2001-05-29 | 2002-12-05 | Boehringer Ingelheim International Gmbh | Carbazole derivatives and their use for the preparation of pharmaceutical compositions for the treatment of npy related diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101166528A (zh) | 2008-04-23 |
| EP1881826A1 (en) | 2008-01-30 |
| IL186072A0 (en) | 2008-08-07 |
| CA2604562C (en) | 2013-09-17 |
| ITMI20050909A1 (it) | 2006-11-20 |
| IL186072A (en) | 2012-05-31 |
| ES2347174T3 (es) | 2010-10-26 |
| PT1881826E (pt) | 2010-08-05 |
| CN101166528B (zh) | 2011-06-15 |
| AU2006246688A1 (en) | 2006-11-23 |
| UA94044C2 (ru) | 2011-04-11 |
| JP2008540591A (ja) | 2008-11-20 |
| JP5086991B2 (ja) | 2012-11-28 |
| KR101312579B1 (ko) | 2013-09-30 |
| KR20080018898A (ko) | 2008-02-28 |
| SI1881826T1 (sl) | 2010-10-29 |
| WO2006122680A1 (en) | 2006-11-23 |
| GEP20094738B (en) | 2009-07-27 |
| MX2007013491A (es) | 2008-01-24 |
| PL1881826T3 (pl) | 2010-12-31 |
| CA2604562A1 (en) | 2006-11-23 |
| AR054126A1 (es) | 2007-06-06 |
| US20080287518A1 (en) | 2008-11-20 |
| BRPI0609718A2 (pt) | 2011-10-18 |
| EP1881826B1 (en) | 2010-07-14 |
| DE602006015457D1 (de) | 2010-08-26 |
| HK1119571A1 (en) | 2009-03-13 |
| ATE473739T1 (de) | 2010-07-15 |
| EA200702534A1 (ru) | 2008-04-28 |
| AU2006246688B2 (en) | 2011-09-22 |
| US8686021B2 (en) | 2014-04-01 |
| DK1881826T3 (da) | 2010-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brogden | Pyrazolone derivatives | |
| JP6082347B2 (ja) | ポリ不飽和長鎖ケトンを用いるリウマチ性関節炎の治療 | |
| KR101853971B1 (ko) | 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도 | |
| EA003251B1 (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ п-АМИНОФЕНОЛА ДЛЯ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ИСПОЛЬЗУЕМЫХ ПРИ ЛЕЧЕНИИ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| NO175148B (no) | Fremgangsmåte for fremstilling av et indomethacinsalt av et toverdig metall valgt fra kobber, sink, kobolt og nikkel | |
| CN116115619B (zh) | 利培酮在治疗器官纤维化中的应用 | |
| EA012724B1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2 (pge2) | |
| TW200400817A (en) | Use of selective EP4 receptor agonists for the treatment of liver failure loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | |
| US5426113A (en) | Method of preventing ulcer formation caused by nonsteroidal antiinflammatory drugs employing tetrazol-benzothiophene carboxamide compounds | |
| JPH06509110A (ja) | 胃及び十二指腸障害を治療する方法及び組成物並びに新規なｐｇｅ↓２誘導体 | |
| CN116392462A (zh) | 毛兰素在制备治疗肺动脉高压的药物中的应用 | |
| CN111632052A (zh) | 胡椒碱在制备sEH抑制剂中的应用 | |
| EP1024807B1 (en) | Use of the compound 2-methoxyphenyl-1-methyl-5p-methylbenzoyl-pyrrol-2-acetamido acetate for the production of an anti-inflammatory drug with prevention of gastric hypersecretion and renal impairment | |
| JP2006509720A (ja) | 潰瘍治療用プロトンポンプ阻害剤としての環付加ピロール化合物 | |
| Eduard et al. | Pineal hormone melatonin as universal modulator of any pathological processes | |
| JPS6388137A (ja) | 非ステロイド系抗炎症剤を含む医薬製剤 | |
| Pepper | NONSTEROIDAL ANTIINFLAMMATORY DRUGS: New Perspectives on a Familiar Drug Class | |
| Cullen, L. & Forde | Non-steroidal anti-inflammatory drugs and the role of cyclo-oxygenase-2 | |
| JP2022125076A (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| US20210179623A1 (en) | New chemical compound containing active enantiometer s-(-) ketorolac tromethamine for the treatment of pain | |
| JPH03364B2 (enExample) | ||
| Matsui et al. | Does gastric acid secretion accelerate NSAID-induced tissue peroxidation in rat stomach? | |
| de La Lastra et al. | Effects of selective and non-selective COX-1 and COX-2 inhibitors on chronic gastric ulcer healing | |
| JPS59106419A (ja) | 消化器の炎症および潰瘍の治療剤 | |
| ITRM980745A1 (it) | Uso di amtolmetine guacil per la produzione di farmaci ad effetto antiinfiammatorio nelle infiammazioni intestinali. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |